Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

15-Year watch begins for CAR T-Cell therapy recipients

NCT ID NCT06652633

Knowledge-focused Sponsor: Lakefront Biotherapeutics NV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring to meet safety guidelines for gene therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 546 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jul 2039

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants who have been treated with a Galapagos CAR T-cell therapy in a clinical trial or Managed Access Program. Exclusion Criteria: * There are no exclusion criteria for this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Academisch Medisch Centrum (Amsterdam UMC)

    RECRUITING

    Amsterdam, 1105 AZ, Netherlands

  • Algemeen Ziekenhuis Delta

    RECRUITING

    Roeselare, 8800, Belgium

  • Antwerp University Hospital

    RECRUITING

    Edegem, 2650, Belgium

  • Centre Hospitalier Universitaire (CHU) De Liège

    RECRUITING

    Liège, 4032, Belgium

  • Cliniques Universitaires Saint-Luc

    RECRUITING

    Woluwe-Saint-Lambert, 1200, Belgium

  • Erasmus Medisch Centrum

    RECRUITING

    Rotterdam, 3015, Netherlands

  • Hospital Clinic De Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Leids University Medical Center (LUMC)

    RECRUITING

    Leiden, 2333 ZA, Netherlands

  • Tufts Medical Center

    RECRUITING

    Boston, Massachusetts, 02111, United States

  • Universitair Ziekenhuis Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • helsingin yliopistollinen sairaala comprehensive cancer center (HUS)

    RECRUITING

    Helsinki, 00290, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.